Financial reports
10-K
2021 FY
Annual report
9 Mar 22
10-Q
2021 Q3
Quarterly report
3 Nov 21
10-Q
2021 Q2
Quarterly report
4 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
11 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
12 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
Current reports
8-K
Termination of a Material Definitive Agreement
22 Mar 22
8-K/A
Entry into a Material Definitive Agreement
15 Feb 22
8-K
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
14 Feb 22
8-K
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
20 Jan 22
8-K
Regulation FD Disclosure
21 Dec 21
8-K
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
3 Nov 21
8-K
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
21 Oct 21
8-K
Other Events
27 Sep 21
8-K
Regulation FD Disclosure
21 Sep 21
8-K
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada
9 Sep 21
Registration and prospectus
15-12B
Securities registration termination
1 Apr 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
POS AM
Prospectus update (post-effective amendment)
23 Mar 22
25-NSE
Exchange delisting
22 Mar 22
SC 14D9/A
Tender offer solicitation (amended)
21 Mar 22
Proxies
DEF 14A
Definitive proxy
22 Jun 21
DEFA14A
Additional proxy soliciting materials
15 Jul 20
DEF 14A
Definitive proxy
17 Jun 20
PRE 14A
Preliminary proxy
1 Jun 20
DEFA14A
Additional proxy soliciting materials
17 Jul 19
DEF 14A
Definitive proxy
17 Jun 19
PRE 14A
Preliminary proxy
7 Jun 19
DEF 14A
Definitive proxy
2 Jul 18
PRE 14A
Preliminary proxy
20 Jun 18
DEFA14A
Additional proxy soliciting materials
3 May 18
Other
EFFECT
Notice of effectiveness
28 Mar 22
EFFECT
Notice of effectiveness
16 Sep 19
CORRESP
Correspondence with SEC
11 Sep 19
UPLOAD
Letter from SEC
1 Aug 19
CT ORDER
Confidential treatment order
18 Apr 18
CT ORDER
Confidential treatment order
5 Sep 17
CT ORDER
Confidential treatment order
27 Mar 17
CT ORDER
Confidential treatment order
21 Sep 16
CT ORDER
Confidential treatment order
12 Apr 16
EFFECT
Notice of effectiveness
13 Jul 15